BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17308070)

  • 1. Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo.
    Rajecki M; Kanerva A; Stenman UH; Tenhunen M; Kangasniemi L; Särkioja M; Ala-Opas MY; Alfthan H; Sankila A; Rintala E; Desmond RA; Hakkarainen T; Hemminki A
    Mol Cancer Ther; 2007 Feb; 6(2):742-51. PubMed ID: 17308070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
    Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
    Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells.
    Iguchi K; Sakurai F; Tomita K; Katayama K; Yamaguchi T; Kawabata K; Tagawa M; Kawabata M; Shirakawa T; Mizuguchi H
    Cancer Gene Ther; 2012 Feb; 19(2):118-25. PubMed ID: 22076042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.
    Lamfers ML; Grill J; Dirven CM; Van Beusechem VW; Geoerger B; Van Den Berg J; Alemany R; Fueyo J; Curiel DT; Vassal G; Pinedo HM; Vandertop WP; Gerritsen WR
    Cancer Res; 2002 Oct; 62(20):5736-42. PubMed ID: 12384532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo.
    Witlox AM; Van Beusechem VW; Molenaar B; Bras H; Schaap GR; Alemany R; Curiel DT; Pinedo HM; Wuisman PI; Gerritsen WR
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):61-7. PubMed ID: 14734452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.
    He X; Liu J; Yang C; Su C; Zhou C; Zhang Q; Li L; Wu H; Liu X; Wu M; Qian Q
    Hum Gene Ther; 2011 Mar; 22(3):283-92. PubMed ID: 20846024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.
    Guse K; Ranki T; Ala-Opas M; Bono P; Särkioja M; Rajecki M; Kanerva A; Hakkarainen T; Hemminki A
    Mol Cancer Ther; 2007 Oct; 6(10):2728-36. PubMed ID: 17938266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
    Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
    Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses.
    Höti N; Chowdhury WH; Mustafa S; Ribas J; Castanares M; Johnson T; Liu M; Lupold SE; Rodriguez R
    Cancer Gene Ther; 2010 Aug; 17(8):585-97. PubMed ID: 20448671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency.
    Suzuki K; Fueyo J; Krasnykh V; Reynolds PN; Curiel DT; Alemany R
    Clin Cancer Res; 2001 Jan; 7(1):120-6. PubMed ID: 11205899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
    Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
    Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replication-competent Ad11p vector (RCAd11p) efficiently transduces and replicates in hormone-refractory metastatic prostate cancer cells.
    Sandberg L; Papareddy P; Silver J; Bergh A; Mei YF
    Hum Gene Ther; 2009 Apr; 20(4):361-73. PubMed ID: 19199789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment.
    Davydova J; Le LP; Gavrikova T; Wang M; Krasnykh V; Yamamoto M
    Cancer Res; 2004 Jun; 64(12):4319-27. PubMed ID: 15205347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
    Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
    Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy using adenovirus against malignant mesothelioma.
    Gotoh A; Kanno T; Nagaya H; Nakano T; Tabata C; Fukuoka K; Tagawa M; Nishizaki T
    Anticancer Res; 2012 Sep; 32(9):3743-7. PubMed ID: 22993314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
    Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
    Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
    Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.